Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies.
Prior to this licensing agreement, BeOne Medicines had obtained a license to use Biocytogen’s RenMice® fully human antibody platform. Building on this established collaboration, the new agreement expands the partnership into antibody license, further strengthening the strategic relationship between the two companies.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “BeOne Medicines is a global leader in drug development, and we are thrilled to enter into this strategic collaboration. The antibodies licensed under this agreement were discovered using our proprietary RenMice® fully human antibody platform, highlighting our ability to empower partners in driving innovative drug discovery. We look forward to seeing these promising molecules progress rapidly into the clinic and ultimately bring transformative treatment options to patients worldwide.”
Under the terms of the agreement, Biocytogen will receive an upfront payment from BeOne Medicines. In addition, Biocytogen is eligible to receive development and regulatory milestone payments, commercial milestone payments, and tiered royaltiesbased on future net sales of licensed products.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250709188805/en/
Contacts
Biocytogen Contacts
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Group Appoints Oddone Incisa as CFO10.7.2025 15:14:00 EEST | Press release
Barilla Group is pleased to announce the appointment of Oddone Incisa as our new Chief Financial Officer, effective September 15, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710908942/en/ Oddone Incisa - Chief Financial Officer, Barilla Group Oddone brings over 25 years of global leadership in finance and risk management, with executive roles, including CFO and CEO positions across Europe and the Americas. His track record includes leading major transformation initiatives and driving organic and inorganic growth. Most recently he served as group CFO of CNH Industrial NV (NYSE: CNH) since March 2020 through May 2025. "Oddone’s appointment reflects our commitment to integrating financial strategy, digital innovation, and sustainability under unified leadership," said Gianluca Di Tondo, CEO of Barilla."His international experience and transformation expertise will be invaluable as we continue to pursue our long-term gro
NETSCOUT Advances AI-Driven Network Operations for TM Forum’s NeuroNOC: The Self-Healing Network Brain Catalyst Project10.7.2025 15:05:00 EEST | Press release
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT), a leading provider of observability, AIOps, cybersecurity, and DDoS attack protection solutions, today announced its recent participation in TM Forum’s NeuroNOC Catalyst, an innovation project at DTW Ignite 2025, which set records for having the most Communication Service Providers and countries represented at a DTW Ignite event. TM Forum is a global alliance of telco and tech companies, leading the industry in defining the building blocks for new operating models, impactful new partnerships, and advanced software platforms. The NeuroNOC Catalyst project explored how AI agents, closed-loop automation, and high-quality network data can enable self-healing operations across telecom environments. Developed in collaboration with global leaders, including Amazon Web Services, Accenture, Symphonica, and Sand Technologies—and championed by carriers such as BT Group, Telecom Argentina, Omantel, Turknet, Axian Telecom, and Safaricom—the NeuroNOC initiative
Ant Group Recognized for Best AML Technology Initiative in Asia Pacific and Best GRC Implementation in China10.7.2025 14:43:00 EEST | Press release
Ant Group has been recognized by The Asian Banker as the Best Anti-Money Laundering (AML) Technology Initiative in Asia Pacific for its advanced AML system, and as having the Best Enterprise Governance, Risk, and Compliance (GRC) Implementation in China for its unified indicator management platform, RiskKey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710291925/en/ Ant Group was recognized for the Best AML Technology Initiative in Asia Pacific and the Best GRC Implementation in China. Ant Group has implemented a unified AML framework by integrating AI, image computing and large language model technologies, and has applied it to its global operations across multiple industries. By standardizing risk indicators and automating suspicious transaction reporting, Ant Group has reduced compliance preparation time by nearly 30% and increased the speed of strategic decision-making by 90%. Using intelligent tools such as RiskKey
Newly Elected Directors of Sinovac Hold the First Board Meeting10.7.2025 14:23:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the new Directors), held its first meeting today at the Company's headquarters in Beijing. This meeting is the first Board meeting held after the new Directors were elected to the Board at the Special Meeting of the Company held on July 8, 2025, at 8:00 p.m. Atlantic Standard Time. At the Special Meeting, 33,248,861 votes (or 54.71% of the total votes present and voting at the Special Meeting) were voted in favor of the election of the new Directors. The meeting was attended by eight of the ten new Directors, and another new Director who was absent from the meeting due to a schedule conflict expressed his suppo
MultiBank Group Announces Early Access Waitlist for Pioneering $MBG Token10.7.2025 13:30:00 EEST | Press release
MultiBank Group, the world’s largest financial derivatives institution headquartered in Dubai, has opened the waitlist for its highly anticipated $MBG Token, ushering in a new era that bridges traditional finance and blockchain technology. The presale will take place in July 2025, with priority access now available at: token.multibankgroup.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710986556/en/ MultiBank Group Announces Early Access Waitlist for Pioneering $MBG Token Unlike typical speculative offerings, the $MBG Token stands apart as a next-generation utility token, supported by tangible assets worth $29 billion and daily trading volumes exceeding $35 billion (as of April 2025). It is designed to introduce genuine revenue streams, advanced infrastructure, and market-level trust to the digital asset space. The $MBG Token is built on MultiBank Group’s robust ecosystem, which spans four core domains: MultiBank Tra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom